NOVARTIS

The radiopharmaceuticals market was valued at USD 5.0 billion in 2023 and is projected to reach USD 16.6 billion by 2032, growing at a CAGR of 10.4%. The market is driven by increasing cancer cases and advancements in diagnostic and therapeutic radiopharmaceuticals. Technetium-99m dominates the market due to its wide diagnostic applications. North America holds the largest market share, while Asia Pacific is the fastest-growing region. Key players include GE Healthcare, Curium Pharma, and Lantheus.

The 'Chronic Urticaria: Competitive Landscape' report by ResearchAndMarkets.com details the current and future therapeutic market, highlighting key players like Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair). With over 60 million diagnosed cases in 16 countries, the report covers 42 pipeline molecules, including 3 in Phase III and 17 in Phase II. The US leads in trial sites for chronic urticaria, followed by China. The report also analyzes acquisition deals and provides strategic insights for market players.

Pharmaceutical companies are conducting clinical trials in Brazil and Turkey due to lower costs. Regulatory reforms by TITCK and ANVISA streamline approval processes, attracting major firms like AstraZeneca and Merck. Phase 3 trials for cancer drugs like Aflibercept and Savolitinib are underway. Collaboration with local institutions and CROs enhances trial quality and efficiency, positioning these countries as key clinical research hubs.

DelveInsight's 'Pompe Disease Pipeline Insights, 2024' covers 15+ companies and 20+ pipeline drugs, including clinical and nonclinical stage products. Key companies include Spark Therapeutics, Amicus Therapeutics, and Asklepios Biopharmaceutical. Recent updates include study results from Astellas Gene Therapies, Amicus Therapeutics, and Genzyme. Pompe disease is a rare genetic disorder with treatments like enzyme replacement therapy.

DelveInsight's 2024 Alzheimer's Disease Pipeline Insight report details 110+ companies developing 120+ therapies, including Neurodon, Sangamo Therapeutics, and others. Key therapies like NRDN-201, ST-501, and Blarcamesine are in various clinical phases. Regulatory milestones include FDA's conventional approval of Leqembi in 2023. The report covers drug mechanisms, clinical studies, and market dynamics.

The global immunomodulators market is projected to grow from $317.06 billion in 2024 to $1,237.66 billion by 2034, driven by their use in treating autoimmune diseases, cancer, preventing infections, and managing organ transplant rejection. Key factors include advancements in precision medicine, regional growth in Asia-Pacific, and recent acquisitions and partnerships in the sector.

Resolution Therapeutics raises £63.5 million in Series B financing led by Syncona Ltd. to advance RTX001, a first-in-class macrophage therapy for end-stage liver disease, into Phase I/II EMERALD study. Proceeds also support manufacturing and pipeline expansion into other inflammatory and fibrotic diseases. Paul Sekhri appointed as Chair of the Board of Directors.

Triveni Bio secures $115m in Series B funding to advance preclinical antibody candidates for immunological and inflammatory diseases, including TRIV-573 targeting KLK5/7 and IL-13. Competitors like Johnson & Johnson are also active in the atopic dermatitis space. The bispecific antibody market is booming, with 1,147 oncology trials listed by GlobalData.

The global Transdermal Drug Delivery market is projected to grow from $80.6B in 2023 to $235.3B by 2030, driven by chronic disease prevalence, technological advancements, and non-invasive delivery benefits. The report provides insights on market trends, regional analysis, and key players.